Novo Nordisk (NOV.DE XETRA) pre-market: earnings due Feb 4, watch €50.12 support

NOV.DE stock opens pre-market on 03 Feb 2026 with €50.12 on the tape and the company set to report earnings on 04 Feb 2026. Investors will focus on diabetes and obesity sales growth and guidance after a 1‑year decline of -37.53% despite a recent 1‑month gain of 11.48%. We flag valuation, EPS, and near-term catalysts ahead of the report and show where analysts and our model see risk and upside.

Earnings preview: NOV.DE stock and the Feb 4 report

Novo Nordisk (NOV.DE) reports on 04 Feb 2026, and the key metric to watch is diabetes and obesity revenue given recent product momentum. Market consensus is expecting another strong top-line contribution from obesity treatments, which will determine guidance changes and near-term volatility. We expect the company to reference geographic growth in North America and Mainland China as drivers of revenue, and any margin commentary will move the stock on XETRA trading.

What to watch in the report: revenue, EPS and guidance

One clear focus is EPS versus the reported EPS €3.13 and trailing PE 15.98; an upside surprise on EPS would likely re-rate the multiple. Free cash flow trends matter because Novo Nordisk shows free cash flow per share €14.11 and a dividend per share €11.65, which underpin yield and buyback optionality. Management commentary on supply, pricing, and R&D for rare disease programs will determine whether guidance tightens or loosens.

Valuation and fundamentals: NOV.DE stock analysis

Novo Nordisk currently trades at €50.12 with market cap €222.21B and a trailing price/sales of 5.26 and price/book near 9.77. These metrics sit below some healthcare peers on PE but above sector medians on PB, reflecting high profitability and strong ROE of 66.95%. Growth remains substantial: 2024 revenue growth was 25.03%, but one‑year share performance is -37.53%, which compresses expectations into the upcoming print.

Technicals and trading setup for pre-market traders

Technically NOV.DE stock shows overbought indicators with RSI 77.16 and short-term momentum strong; the 50‑day average is €45.48 and the 200‑day average is €50.77. Key intraday levels to monitor on XETRA are support near €48.00 and resistance at the day high €50.34. Volume pre-market is subdued relative to average volume 421,729, which means earnings-driven moves could widen spreads.

Risks and catalysts affecting NOV.DE stock

Primary upside catalysts are better-than-expected obesity drug uptake, improved gross margins, and bullish 2026 guidance. Downside risks include pricing pressure, regulatory setbacks in key markets, and a weaker macro healthcare spend environment. Other material risks are inventory cycles—the company reports long days of inventory 306 days—and potential FX swings given global sales exposure.

Meyka Grade & forecast for NOV.DE stock

Meyka AI rates NOV.DE with a score out of 100: 74.35 (B+, BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly price of €51.97, implying +3.69% versus the current €50.12; forecasts are model-based projections and not guarantees.

Final Thoughts

Key takeaways for NOV.DE stock ahead of the 04 Feb 2026 earnings: first, the market will price any revenue or EPS beats quickly because the shares trade near the 200‑day average €50.77 and carry a trailing PE 15.98 that allows room for re-rating. Second, cash generation is a strength with free cash flow per share €14.11 and a dividend supporting income investors. Third, technicals show short-term overbought conditions so expect volatility after the release. Meyka AI’s model projects a near-term target of €51.97 (+3.69%); a conservative 12‑month target of €68.00 reflects product uptake and multiple expansion, while a downside trigger would be a close below €48.00. These forecasts are model-based projections and not guarantees. For a real-time tracker and fuller metric set see our NOV.DE stock page on Meyka AI and follow the Reuters briefing for confirmation of figures Reuters and longer-form context at Seeking Alpha Seeking Alpha.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.